摘要
目的评价托拉塞米短期应用于充血性心力衰竭的有效性和安全性。方法检索PubMed、Cochrane Library、中国知网、万方及维普数据库从建库至2021年4月托拉塞米治疗充血性心力衰竭的研究,经文献筛选和资料提取后,使用RevMan 5.4软件对纳入研究进行meta分析。结果共纳入9个随机对照试验,meta分析结果显示:与呋塞米相比,托拉塞米治疗充血性心力衰竭总有效率提高(RR=1.32,95%CI:1.21~1.43,P<0.00001),24 h尿量增量提高(MD=283.26,95%CI:255.08~311.43,P<0.00001),降血钾作用较弱(MD=0.67,95%CI:0.42~0.91,P<0.00001),不良反应发生率降低(RR=0.31,95%CI:0.12~0.82,P=0.02)。结论托拉塞米治疗充血性心力衰竭使总有效率提高,利尿效果更好,同时安全性较好。
Objective To evaluate the efficacy and safety of short-term application of torasemide in congestive heart failure(CHF).Methods The researches on torasemide in the treatment of CHF in PubMed,Cochrane Library,China National Knowledge Internet(CNKI),Wanfang and VIP Metabases were searched from the establishment of the database to April 2021.After literature screening and data extraction,RevMan 5.4 software was used to carry out meta-analysis on the included studies.Results Nine randomized controlled trials were included.Meta analysis showed that compared with furosemide,the total effective rate of torasemide in the treatment of CHF was higher(RR=1.32,95%CI:1.21-1.43,P<0.00001),and the increment of urine volume in 24 hours was higher(MD=283.26,95%CI:255.08-311.43,P<0.00001).Meanwhile,compared with furosemide,the effect of lowering blood potassium of torasemide was weaker(MD=0.67,95%CI:0.42-0.91,P<0.00001),and the incidence of adverse reactions was lower(RR=0.31,95%CI:0.12-0.82,P=0.02).Conclusion Torasemide can improve the total effective rate,with sound diuretic effect and higher safety in the treatment of CHF.
作者
朱春红
陈向凡
陈霞
ZHUChunhong;CHENXiangfan;CHENXia(Department of Pharmacy,the First People’s Hospital of Nantong,Jiangsu,Nantong 226001,China)
出处
《中国医药科学》
2022年第2期38-41,84,共5页
China Medicine And Pharmacy
基金
江苏省南通市市级科技计划(指导性)项目(JCZ20076)。
